Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04529018
Other study ID # CETO-FIH
Secondary ID 2018-004851-18IS
Status Recruiting
Phase N/A
First received
Last updated
Start date August 3, 2020
Est. completion date November 30, 2020

Study information

Verified date August 2020
Source University of Cambridge
Contact Martin Thomas, PhD
Phone 01223 254 920
Email martin.thomas@addenbrookes.nhs.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a Phase 1, single-centre, open label, micro-dosing study. The aim is to investigate an innovative new tracer, [18F]CETO, as a potential alternative to adrenal vein sampling for the lateralisation of primary aldosteronism (PA).


Description:

At least one-quarter of the UK adult population has hypertension, a major risk factor for heart attacks and stroke. Primary aldosteronism (PA), a treatable form of hypertension, accounts for 5-10% of all cases, and 20-25% of difficult to control hypertension. It is challenging to determine whether one adrenal gland is the source of PA (which is potentially curable with surgery) or both glands (which would require long-term drug treatment). Existing lateralising procedures (i.e. investigations to distinguish one from two gland involvement e.g. CT or MRI scan) have significant limitations. Accordingly, most patients must undergo an invasive procedure called adrenal vein sampling (AVS) in which small catheters are placed in each adrenal vein. However, this is time-consuming, technically demanding, and fails in 20-50% of cases. To address this, researchers have adopted a novel approach using PET-CT as an alternative to AVS. Currently, this uses a tracer called metomidate labelled with carbon-11 (11C MTO), which is taken up preferentially by the adrenal gland, and in particular by adrenal tumours causing PA. However, its utility is limited by a short half-life, which means the scan can only be performed in centres with a cyclotron facility (currently less than 10 NHS sites). The aim of this study is to investigate the safety of a new tracer with a longer half-life, [18F]CETO, that could be made available for use in many more centres.

The trial objectives are outlined below:

Primary Objective

To evaluate the safety of up to two administrations of [18F]CETO in up to 6 patients with primary aldosteronism and 5 healthy volunteers.

Secondary Objective

- Assess [18F]CETO uptake by the adrenal glands

- Evaluate uptake in bilateral vs unilateral cases of PA following [18F]CETO administration in up to 6 patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 11
Est. completion date November 30, 2020
Est. primary completion date November 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years and older
Eligibility Healthy Volunteers

To be included in the trial the participant must:

- give written informed consent

- be aged 50 years or over

- have no underlying medical conditions

- be able to lie down for at least 2 hours and not be claustrophobic

In addition, all female participants must be:

- post-menopausal (no menses for 12 months, without an alternative medical cause)

Patients

To be included in the trial the patient must:

- give written informed consent

- be aged 40 years or over

- be able to lie down for at least 2 hours and not be claustrophobic

fulfil the following criteria:

- have a confirmed diagnosis of PA as per Endocrine Society guidelines

- At least one paired measurement of plasma renin and aldosterone, measured off Spironolactone/Eplerenone within past 12 months, showing ARR above local threshold value.

- One of the following two criteria:

- Plasma aldosterone>190pmol/L following saline infusion.

- Spontaneous hypokalaemia, suppressed plasma renin and plasma aldosterone>550pmol/L.

- have undergone successful lateralisation of the cause of PA to one or both adrenal glands by adrenal vein sampling (AVS).

- be willing to have two scans

In addition, all female patients must have a negative (blood) pregnancy test at the screening visit.

Exclusion Criteria:

All participants:

- allergy to radiographic contrast agents

- allergy or contraindication to synacthen

- pregnancy, breastfeeding, or the intention to become pregnant during the 6 months following trial participation

- positive pregnancy test at the screening or baseline visits

- assessed by the investigator as being unable or unwilling to comply with the requirements of the study protocol.

- receipt of another IMP as part of a CTIMP

- prior radiation exposure as part of previous research studies

- recreational drug use, or substance/alcohol dependency

- clinically abnormal screening blood tests.

Additional exclusion criteria for healthy volunteers:

- women of child-bearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile)

- exposure to radiation during their work

- received more than 10 mSv of radioactivity in the past 12 months

- any subject with a history of adrenal disease or who, at the screening visit, reports symptoms, or exhibits physical signs, that could be consistent with previously unsuspected adrenal disease

Additional exclusion criteria for patients:

- allergy or contraindication to dexamethasone treatment (or lactose intolerant)

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
[18F]CETO
[18F]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism

Locations

Country Name City State
United Kingdom Addenbrooke' Hospital Cambridge Cambridgeshire

Sponsors (2)

Lead Sponsor Collaborator
University of Cambridge Cambridge University Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (3)

Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerström G, Långström B. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med. 2000 Feb;41(2):275-82. — View Citation

Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, Azizan EA, Aigbirhio F, Gurnell M, Brown MJ. Evaluation of the sensitivity and specificity of (11)C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab. 2012 Jan;97(1):100-9. doi: 10.1210/jc.2011-1537. Epub 2011 Nov 23. — View Citation

Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H, Beuschlein F, Zink M, Lang K, Allolio B, Schirbel A. [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab. 2008 Jun;93(6):2358-65. doi: 10.1210/jc.2008-0050. Epub 2008 Apr 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of [18F]CETO administration The primary outcome measure is the overall safety of [18F]CETO. This will be assessed according to the frequency of adverse events, serious adverse events, clinically significant changes in vital signs, ECG and laboratory parameters. 6 months
Secondary [18F]CETO uptake by the the adrenal glands. [18F]CETO uptake by the adrenal glands will be assessed by measurement of Standardized Uptake Values (SUV) over the left and right adrenal glands. All assessments will be performed by a dedicated blinded reviewer. 6 months
Secondary To evaluate uptake in bilateral versus unilateral cases of PA following [18F]CETO administration in up to 6 patients. Evaluation of adrenal uptake of [18F]CETO in bilateral versus unilateral cases of PA will be performed by comparing SUV values of both adrenal glands in three patients with each subtype of PA (using a dedicated blinded reviewer). 6 months
See also
  Status Clinical Trial Phase
Completed NCT02885662 - Study of CS-3150 in Patients With Primary Aldosteronism N/A
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Completed NCT01728493 - Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment N/A
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT06047912 - Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone
Recruiting NCT04991961 - Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Screening for Primary Aldosteronism
Recruiting NCT05405101 - Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA N/A
Recruiting NCT05501080 - The Effect of SAAE on Ventricular Remodeling in PA Patients N/A
Recruiting NCT05973604 - Prevalence of Primary Aldosteronism in Atrial Fibrillation
Recruiting NCT05826080 - Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism
Completed NCT04179019 - Calcium Channel Blockade in Primary Aldosteronism Phase 2
Completed NCT03500120 - Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Completed NCT05435703 - Renal Cysts and Primary Aldosteronism
Recruiting NCT02945904 - IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
Enrolling by invitation NCT02257450 - Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study N/A
Recruiting NCT05561361 - The Effect of SAAE on Vascular Endothelial Function in PA Patients
Completed NCT03398785 - Adrenal Artery Ablation Treats Primary Aldosteronism Phase 3
Recruiting NCT03224312 - Chongqing Primary Aldosteronism Study
Recruiting NCT04428827 - Outcome of Patients With Primary Aldosteronism